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Abstract
Backgrounds: Tumor-positive sentinel node(SLN) biopsy results in a risk of nonsentinel node metastases in case of
micro and macro metastases ranging from 20 to 50 %, respectively. Therefore, most patients underwent unnecessary
axillary lymph node dissections.
Thus, the development of a mathematical model for predicting patient-specific risk of non sentinel node(NSLN)
metastases is strongly warranted.
Methods: The following parameters were recorded:
– Clinical: hospital, age, medical record number
– Bio-pathological: tumor (T) size, grading (G), multifocality, histological type, LVI, ER-PR status, HER-2, ki67, molecular
classification (luminal A, luminal B, HER2 like, triple negative)
– Sentinel and nonsentinel lymph node related: number of removed SLNs, number of positive and negative SLNs,
copy number of positive sentinel nodes, ratio: number of positive SLNs to number of removed SLNs, number of
removed and number of positive nodes after ALND. A total of 2460 patients have been included in the database.
All the patients have been provided by the authors of this paper.
Results: Multivariate logistic regression analysis demonstrated that only the number of a CK19 mRNA copies (p < 0.0001),
T size (p < 0.0001) and LVI (p < 0.0001) were associated with NSN metastases.
The discrimination of the model, quantified with the area under the receiver operating characteristics curve, was 0.71
(95 %, C.I. 0.69–0.73), thus confirming a good level of reliability.
Conclusions: The nomogram may be employed by the surgeon as a decision making tool on whether to perform an
intraoperative axillary lymph node dissection on breast cancer patients with SLN positive.
The large population employed and the standardized method of measuring the value of CK19 mRNA copies are
appropiate prerequisites for a reliable nomogram.
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Background
Breast cancer is one of the most frequent neoplasm in
women, generally treated with quadrantectomy or mast-
ectomy [1].
Sentinel lymph node (SLN) biopsy is a highly accurate
predictor of overall axillary status and has become the
standard axillary staging method for the last 15 years in
breast cancer (BC) patients who are confirmed clinically
negative for lymph node metastases [2, 3]. In the case of
negative SLN, patients can safely avoid axillary lymph
node dissection (ALND), thus preventing associated
morbidity [4]. However, approximately 50–70 % of
patients with positive SLN have no additional positive
nodes, suggesting that it may be possible to avoid ALND
in selected patients [5, 6]. Taking these considerations
into account, an accurate estimate of the likelihood of
additional node metastases may be of paramount import-
ance when deciding further treatment. At the present
time, the intraoperative decision on, whether to perform
ALND or not, is often only based on the positivity of the
SLN. In order to assess the SLN status more rapidly, a
semi-automated molecular method called the one step
nucleic acid amplification (OSNA) assay has recently been
made available [7–11]. On the basis of these consider-
ations, the European OSNA Committee decided to de-
velop a new nomogram able to predict the non sentinel
node (NSN) status, including the number of CK 19 mRNA
copies as the most powerful parameter. The aim of the
study was to report the results of the retrospective phase
of the Nomogram Project, as the validation phase is
ongoing.
Methods
The European OSNA Users Committee decided to develop
a Nomogram Project with the following aims:
– To create new predictive factors for NSN positivity
(copy number of CK19 mRNA) as well assessing the
conventional histopathological parameters.
– To develop a user-friendly nomogram to predict
NSN positivity based on the CK19 mRNA copy
determined by OSNA assay tested in large patient
population.
Our study population only included cases that fulfilled
the following criteria: primary invasive cT1-3 BC with
clinically and radiological (preoperative sonogram) nega-
tive axilla; no prior systemic treatment, or axillary sur-
gery; successful SLN biopsy in which metastatic disease
was identified by OSNA; and ALND with at least 10
nodes examined.
The following parameters were recorded:
– Clinical: hospital, age, medical record number
– Bio-pathological: tumor size, grading, multifocality,
histological type, LVI, ER-PR status, HER-2, ki67,
molecular classification (luminal A, luminal B, HER2
like, triple negative)
– SLN and NSN related: number of removed SLNs,
number of positive and negative SLNs, copy number
of positive SLNs, ratio: number of positive SLNs to
number of removed SLNs, number of removed and
number of positive nodes after ALND. A total of
2460 patients have been included in the database.
The biopathological parameters included in the database
are shown in Tables 1 and 2.
Twenty-two European centers contributed to the enroll-
ment of patients between January 2008 and February
2013; 2460 patients made up the body of nomogram.
Sentinel Lymph Node sampling method
SLNs were identified using technetium 99 m- labeled,
nanosized, human serum albumin colloids. To avoid any
contamination during tumor manipulation, SLNs were
surgically excised before breast surgery and sent on ice
to the Pathology Department.
Each SLN was weighed and measured. SLNs weighing
less than 50 mg were excluded from the study. SLNs
weighing more than 600 mg were cut in two or more
pieces and processed as separate nodes.
One Step Nucleic Acid Amplification
The OSNA assay was performed according to the manu-
facturer’s instructions (Sysmex, Kobe, Japan). In short, the
SLN was homogenized in 4 ml of the LINORHAG hom-
ogenizing buffer (Sysmex) on ice. A small aliquot was used
for automated real- time amplification of CK19 mRNA via
reverse transcription loop-mediated isothermal amplifica-
tion (RT-LAMP) with the ready-to use LYNOAMP
reagent kit (Sysmex) on the RD-100i (Sysmex).
It was possible to analyze up to 4 SLNs in one run.
The degree of amplification was detected via a by-
product of the reaction, i.e. magnesium-pyrophosphate.
After use, the excess lysate was stored at minus 80 °C. A
lysate with CK19 mRNA copy number/μl less than
250 (a) was regarded as negative (score−); from 250
to 5000 (b) as positive (score +), and greater than
5000 (c) (score ++). The OSNA results were immediately
communicated by telephone to the surgeon within
30–40 min. For statistical analysis, in case of two or
more SLNs, the SLN with the greatest CK19 mRNA
copies was chosen.
When there was a positive OSNA result, both for
micrometastases (+) and macrometastases (++) the patients
underwent an immediate ALND. ITC are not detected by
OSNA method. This is not a limitation because patients
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with positive SN for ITC are no longer submitted to
ALND.
Axillary NSNs were routinely examined by H&E.
Statistical analyses
The outcome of our nomogram was the presence of posi-
tive nodes in the axillary dissections following OSNA
evaluation in the population defined above. We identified a
list of potential covariates that may predict this outcome,
thus the endpoint was a binary outcome (presence versus
absence of at least one positive node other than SLN)
and the association with the covariates was analyzed
using a logistic linear model. Continuous variables
(number of CK19 mRNA copies and T size expressed
in mm) were categorized using quartiles. We investigated
the role of each variable and estimated the Odds Ratio
along with the 95 % confidence interval; independent
factors were then identified using a stepwise forward
likelihood ratio method.
Table 1 Clinicopathologic characteristic of patients































Luminal A 1185 48.1
Luminal B 982 39.9
HER2-like 46 1.9
Triple Negative 247 10.1
amultiple stands for multifocality
Table 2 Characteristics of sentinel node and non sentinel node
Number Percent













SLN Micrometastases 977 39.7
SLN Macrometastases 1483 60.3
Median (range) 14 (2–47)
N° of NSLNs removed mean 14.8
N° of positive NSLNs 829 33.7
Median (range) 2 (1–30)
Mean 3.2
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*multiple stands for multifocality
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Discrimination ability was assessed by ROC analysis and
predictive accuracy was measured by the AUC reported
with its 95 % confidence interval. Calibration was evaluated
by reviewing the plot of predicted probabilities versus the
actual probabilities. Well calibrated models have a linear
relationship with a slope of 1 and an intercept of 0. Thus, a
linear regression coefficient between predicted and ob-
served values was estimated.
The resulting model will be validated in a prospective
series. All the analyses were performed using IBM SPSS
version n. 20 [12].
Ethical consideration
The patient data was anonymously gathered retrospectively
with no influence on patient therapy. The Nomogram pro-
ject was approved by Ethical Committee of each participat-
ing institution.
Results
Table 1 shows the clinical and bio-pathological character-
istics of the patients.
The mean and median ages were 56 and 54, respectively
ranging between 22 and 90 years.
The vast majority of the patients were affected with
infiltrating ductal carcinoma (87.0 %). Most of them had
an intermediate (56.7 %) or high grade tumors (27.5 %).
Both Estrogen (ER) and Progesterone (PgR) receptors
were positive in 90 and 80.6 %, respectively, whereas
HER2 was positive only in 6.5 % of the patients. Ki67
was high in 48.3 % and LVI was present in 43.2 % of the
patients. These parameters represent the new molecular
classifications of breast cancer that allow not only to
identify patients at a higher risk of relapse but may also
guide postoperative therapies [13, 14].
Tumor size was divided in quartiles, the cut-offs being
12, 18 and 25 mm.
The mean and median tumor sizes were 20.3 and
18 mm, respectively, ranging between 0.8 and 50 mm.
The SLNs and NSLNs characteristics are reported in
Table 2. Patients with micro or macrometastases in the
SLNs were 977 (39.7 %) and 1483 (60.3 %), respectively.
The median number of examined and positive SLNs
was 1, one SLN was examined in 1273 patients (51.7 %);
2 in 801 (32.6 %); 3 in 277 (11.3 %); 4 in 88 (3.5 %); 5 in
17 (0.7 %); 6 in 4 (0.2 %).
1765 patients (71.8 %) had only 1 positive SLN, 527
(21.4 %) had two, 136 (5.5 %) had three, 29 (1.2 %) had
four and 3 (0.1 %) had five. NSLNs were positive in 829
patients (33.7 %), found both in patients with SLN
micrometastases (22 %) or macrometastases (78 %). The
median and mean number of positive NSLNs were 2
and 3.2, respectively, ranging between 1 and 30.
The mean and median number of NSLNs removed were
14.8 and 14, respectively. The number of CK19 mRNA
copies was divided in quartiles in order to obtained a better
stratification of the patients.
In Table 3 the results of univariate and multivariate
analyses are reported.
Logistic regression model showed that grading (p <
0.0001), Ki67 (p < 0.01), type (p < 0.001), T size (p < 0.0001),
size of metastatic foci (micro or macrometastases) in the
SLN (p < 0.0001) and number of CK19 mRNA copies
(p < 0.0001) were associated with positive NSN status.
Multivariate logistic regression using a Cox model ana-
lysis demonstrated that only the number of CK19 mRNA
copies (p < 0.0001), T size (p < 0.0001) and LVI (p < 0.0001)
maintained their independent value, and therefore
they would be useful to construct the nomogram. We
wanted to build a nomogram that the surgeon could
utilize during the operation, therefore LVI was excluded
because its unreliability was assessed in preoperative
core biopsy only.
According to the clinical-pathological characteristics
of our patients, the predicted probability of NSN positivity
ranges between 9.9 and 64.3 %.
One of the main aim of nomogram is to identify the
subgroup of patients with a low risk of NSN involvement
[15]. When calculating the number of patients with a
probability of metastatic NSN ≤ 10 %, predicted by the
nomogram, 212 patients could be identified in this subset.
Among these patients, 196 patients were truly negative
and only 16 (7.5 %) were falsely negative. It must be em-
phasized that the percentage of 7.5 % is, perfectly super-
imposable to false negative rate of SLN biopsy normally
quoted at 5–10 % [16, 17].
The model showed a sensitivity of 98.1 % and a specifi-
city of 19 %, whilst the positive and negative predict values
were 36.2 and 92.5 %, respectively.
The discrimination of the model, quantified with the
area under receiver operating characteristic (ROC) curve
was 0.71 (95 % c.i. 0.69–0.73) showing a good level of
discrimination (Fig. 1).
The model performed well and correctly both in low and
in high risk cases as shown in the calibration plot. The
linear regression model between has a slope of 0.98 (95 %
c.i. 0.89–1.07) and a constant of 0.01 (95 % c.i. -0.03–0.04)
between predicted and actual probability (Fig. 2).
The significant variables were then incorporated into a
nomogram to predict NSN status (Fig. 3).
Discussion
It is well known that SLN micro- and macrometastases
are associated with mean NSN positivity rate of 20 and
50 %, respectively. Consequently, the dilemma for sur-
geons still persists in how to avoid unnecessary ALND
and how to identify patients at low risk of NSN
positivity.
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Recently, ASCO guidelines for SLNB and ALND have
been published, indicating the patients with micro and
macrometastases (only those that meet Giuliano criteria)
may avoid ALND, but many controversies still remain
[18]. The Z0011 Trial that randomized patients to obser-
vation or ALND after positive SLN, failed to reach its
target accrual. However, the analysis restricted to only
856 patients seemed to demonstrate no differences in
disease-free and overall survival between the two groups
[19]. But the limited number of patients together with
the fact that 97 % of patients received systemic chemo-
therapy and axillary radiotherapy (89 %) obscures the
reliability of the results. Moreover, the results of this
study cannot be applied to subsets of patients like young
women (<50 years), patients undergoing mastectomy,
patients with lobular carcinoma or hormone receptor
negative tumours or HER2 positive tumours, due to
being underrepresented in Z0011 study. Finally in 2012,
the CAGS/ACS Based Review in Surgery Committee
examined the Z0011 trial because its results might be
“practice changing”. A great deal of biases were found
and the final conclusion was: “Should the results of
Z0011 change practice? Owing to its methodological
limitations, if we had to depend on Z0011 alone, the
standard of care following positive sentinel node is still
an ALND” [20]. The same conclusion was reached by a
Table 3 Results of Univariate and Multivariate Analysis
Univariate analysis Multivariate analysis
OR (95 % c.i.) P OR (95 % c.i.) P
HYSTOLOGY 0.44
CDI vs CLI 0.90 (0.69–1.17)
GRADING 0.001
G2 vs G1 1.45 (1.12–1.87) 0.005
G3 vs G1 1.74 (1.32–2.31) <0.0001
ER 0.27
Pos vs neg 1.19 (0.87–1.61)
PgR 0.09
Pos vs neg 1.22 (0.97–1.53)
HER2 0.11
Pos vs neg 0.73 (0.50–1.07)
Ki67 0.01
High vs low 1.29 (1.06–1.56)
T <0.0001 <0.0001
13–18 vs <12 1.31 (1.02–1.67) 0.03 1.10 (0.85–1.43) 0.45
19–25 vs <12 2.04 (1.60–2.60) <0.0001 1.73 (1.34–2.23) <0.0001
>25 vs <12 2.70 (2.10–3.48) <0.0001 2.22 (1.70–2.90) <0.0001
TYPE* 0.001
Multiple vs single 1.55 (1.19–2.02)
LVI <0.0001 n.c.
Yes vs No 2.88 (2.37–3.49)
COPIES <0.0001
Macro (>5000) vs Micro (<=5000) 3.57 (2.95–4.32)
COPIE <0.0001 <0.0001
1500–12,000 vs <1500 2.15 (1.62–2.85) <0.0001 2.15 (1.60–2.87) <0.0001
12,000–111,000 vs <1500 4.26 (3.24–5.62) <0.0001 4.14 (3.12–5.49) <0.0001
>111,000 vs <1500 7.18 (5.46–9.45) <0.0001 6.86 (5.18–9.01) <0.0001
MOLECULAR SUBTYPE 0.05
Luminal A vs triple neg 1.09 (0.76–1.56) 0.64
Luminal B vs triple neg 1.39 (0.97–2.01) 0.07
Her2 vs triple neg 0.76 (0.32–1.80) 0.54
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German, Austrian and Swiss (D, A, CH) consensus panel
in 2013 [21].
Recently, the prospective randomized IBCSG23-01 trial
has been published [22]. Only patients with micrometas-
tases were randomized to either ALND or no further
treatment in patients with positive SLN.
The results of this study demonstrated no differences
between the two arms both in terms of disease-free and
of overall survival.
Some challenges, however, still exist regarding this
study. Patients accrual stopped prematurely and only
933 out of 1960 patients were enrolled, therefore the
study was underpowered.
The patient population had a very good prognosis. In
fact, sentinel tumor size ≤ 1 mm was present in 69 % of
the patients. As a result, the incidence of additional posi-
tive NSN in axillary dissection group was 13 %, very
similar to that found in case of ITCs metastases in SLN.
This is also because the author included ITCs in the
group of micrometastases. A clear correlation between the
size of micrometastases (less or greater than 1 mm) and
positive NSNs was clearly demonstrated by Rahusen and
Viale [23, 24]. Their results confirm that the presence in
the study of 69 % of patients with SLN micrometastases ≤
1 mm is a great bias. The median 5-years follow-up is too
short to assess the real incidence of axillary recurrence in
this study. In NSABP-B6, 20 % of nodal recurrences after
lumpectomy and 24 % of nodal recurrences after lymph-
adenectomy and radiotherapy occurred after 5 years [25].
These data are very consistent with the Dutch Mirror
Fig. 1 ROC curves of number of CK19 mRNA, T size (quartiles) and the model containing these two variables
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study that demonstrated an increased recurrence rate in
patients with micrometastases in the SLN not undergoing
ALND [26].
Taking into account these considerations, accurate es-
timates of the likelihood of additional nodal metastases
may be of paramount importance in the decision making
process regarding further treatment. Nomograms might
be valid prediction tools for surgeons to select patients
that significantly benefit from an ALND after positive
SLN.
The European OSNA Users Committee decided to col-
lect a high number of patients use whose SLNs were all
assessed with OSNA. In fact, our nomogram elaborated
2460 patients.
To the best of our knowledge, this is the largest pro-
spective series in which patients with micrometastases (+)
and macrometastases (++), detected by the OSNA assay,
underwent immediated ALND.
Table 3 shows that multivariate regression Cox analysis
selected the number of CK19 mRNA copies, T size and LVI
as independent prognostic factors. LVI was not employed
to develop the nomogram for its unreliability to assess this
parameter with only a preoperative core biopsy. OSNA
classifies SLN micrometastases when the number of CK19
mRNA copies ranges between 250 and 5000; whereas the
number of copies > 5000 identifies macrometastases.
Therefore, for both micro and macro-metastases there
is a wide range of number of copies, and according to
Fig. 3 Nomogram to calculate the risk percentage of NSN positivity. The score of each of the 2 variables are summed and reported on the total score
raw, immediately below the percentage of NSN positivity is identified
Fig. 2 The model performs well and correctly both at low and in high risk cases as shown in calibration plot. The linear regression model has a slope
of 0.98 (95 %, C.I. 0.89–1.07) and a constant of 0.01 between predicted and actual probabilities (95 %, C.I. 0.03–0.04)
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the number of copies, patients may have different prob-
abilities of positive NSN [11].
In our nomogram, we used the number of copies as a
continuous variable divided in quartiles in order to have
approximately the same number of patients in each sub-
group with a more reliable patient distribution. The use
of SLN size as a continuous variable improved the cap-
acity of nomogram to accurately predict the NSN involve-
ment in patients with positive SLN, as demonstrated by
Mittendorf [27].
The availability of a molecular method which provides
less subjective and quantitative results may be a useful
tool in this context. We also evaluated T size as a
continuous variable dividing patients in quartiles to obtain
a better distribution.
The association of tumor size with the likelihood of
NSN metastasis has been documented in numerous
studies [15, 28–36].
It is readily apparent that the two parameters chosen
for our nomogram reflect the greatest probability to
identify patients with the NSN metastasis.
There are several parameters that permits to evaluate
the reliability of a nomogram.
Discrimination
In our nomogram the AUC is 0.71 (0.69 – 0.73) which is
considered a good value of discrimination and is consist-
ent with the best nomograms published so far [37–43].
Calibration
Calibration determines the distance between predicted
outcome and actual outcome, and has a higher clinical
significance than discrimination [27, 37].
In our nomogram, the mean difference between pre-
dicted and calibrated probabilities was 2.3 %, with a
maximum difference of 4.0 % (Fig. 2). This information
is of clinical utility because it gives the opportunity for
the clinicians to inform the patient regarding both the
predicted probability of NSN metastases and the range
of probability.
False negative rate
It must be emphasized that our nomogram was able to
identify 212 patients with a risk of NSN metastases ≤ 10
%. Only 16 patients were FN (i. e. presence of metasta-
ses) in NSLNs. Therefore, the FN rate is 7.5 %, thus con-
firming the validity of the nomogram to identify patients
that may omit ALND. This makes both the surgeon
comfortable in the decision making process as well as
the patient to accept this decision.
The multivariate logistic regression analysis showed
that the number of copies is an independent predictor of
metastatic NSLNs after adjusting for T size (Fig. 1).
It must be stressed that the number of copies is
assessed intra-operatively. Therefore, the surgeon may
decide on whether to perform an ALND or not in the
same operation, avoiding the psychological impact of a
second operation.
However the result of this nomogram are currently
under external validation to test reproducibility of the
model on a large series of independent prospective data.
This method remains the best choice in validating the
proposed nomogram and in making a reliable instrument
available.
Conclusions
In conclusion, there is still ongoing discussion and debate
among breast cancer surgeons regarding the need to per-
form completion ALND in patients with positive SLN.
This nomogram incorporating SLN tumour burden, de-
fined by OSNA method, is another tool that can be utilized
by surgeons to more effectively counsel individual patients,
thereby personalizing the surgical treatment of breast can-
cer and using this information intra-operatively.
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